# Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Study · id `cardio:ct-nct02104804` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02104804](<https://clinicaltrials.gov/study/NCT02104804>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02104804

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 953 participants.

## Technical summary

Registry record NCT02104804. Randomized; quadruple masking; primary purpose treatment. Start 2014-05-07 (actual); primary completion 2016-02-26 (actual). Results posted on 2017-10-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 953 participants (enrolled count; ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Started: 2014-05-07 (actual) (ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Primary completion: 2016-02-26 (actual) (ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Completion: 2016-02-26 (actual) (ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Results first posted: 2017-10-02 (ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02104804, source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02104804-2017-10-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Saxagliptin 5mg
- Intervention (Drug): Placebo for Saxagliptin
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial (`cardio:pubmed-29144061`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fd5c745a097c4103cf36337a7c877e27f881a51bd8c2177069499e611af6cb51
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
